Immunotherapy response assessment in neuro-oncology: A report of the RANO working group

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages e534-e542

  Okada, Hideho ^a   Weller, Michael ^b   Huang, Raymond ^c   Finocchiaro, Gaetano ^d   Gilbert, Mark R ^e   Wick, Wolfgang ^f   Ellingson, Benjamin M ^g   Hashimoto, Naoya ^h   Pollack, Ian F ⁱ   Brandes, Alba A ^j   Franceschi, Enrico ^j   Herold Mende, Christel ^f   Nayak, Lakshmi ^k   Panigrahy, Ashok ⁱ   Pope, Whitney B ^g   Prins, Robert ^g   Sampson, John H ^l   Wen, Patrick Y ^k   Reardon, David A ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^j IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; IPILIMUMAB; TEMOZOLOMIDE; TICILIMUMAB;

BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG RESPONSE; EDEMA; GLIOBLASTOMA; GLIOMA; HUMAN; MELANOMA; NERVOUS SYSTEM TUMOR; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERITUMORAL EDEMA; PRIORITY JOURNAL; RADIOGRAPHIC PROGRESSION; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION; ALGORITHM; DISEASE COURSE; IMMUNOTHERAPY; NERVOUS SYSTEM NEOPLASMS; PRACTICE GUIDELINE;

ALGORITHMS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NERVOUS SYSTEM NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84960956996     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00088-1     Document Type: Review

References (52)

1. KantoffPW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
4. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
5. Sundar R, Cho BC, Brahmer JR, Soo RA Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015, 7:85-96.
6. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014, 371:1507-1517.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
8. Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glioblastoma. Neuro Oncol 2014, 16:1441-1458.
9. Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 2012, 17:181-202.
10. Jackson CM, Lim M, Drake CG Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 2014, 20:3651-3659.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
13. Macdonald DR, Cascino TL, Schold SC, Cairncross JG Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
14. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
15. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013, 13:347.
16. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
17. van den Bent M, Wefel J, SchiffD, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011, 12:583-593.
18. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015, 16:e270-e278.
19. Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol 2014, 17:151-159.
20. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004, 63:535-537.
21. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
22. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 153:7412-7420.
23. Hoos A Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012, 23(suppl 8):viii47-viii52.
24. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 102:1388-1397.
25. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29:330-336.
26. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
27. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
28. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
29. Okada H, Pollack IF Do we need novel radiologic response criteria for brain tumor immunotherapy?. Expert Rev Neurother 2011, 11:619-622.
30. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
31. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
32. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus Ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014, 2:632-642.
33. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009, 29:1-42.
34. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16:1042-1048.
35. Huang RY, Neagu MR, Reardon DA, Wen PY Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy-detecting illusive disease, defining response. Front Neurol 2015, 6:33.
36. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:4722-4729.
37. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007, 30:1-15.
38. Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014, 32:2050-2058.
39. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008, 10:361-367.
40. van den Bent MJ, Wefel JS, SchiffD, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011, 12:583-593.
41. Kaal EC, Vecht CJ The management of brain edema in brain tumors. Curr Opin Oncol 2004, 16:593-600.
42. Dietrich J, Rao K, Pastorino S, Kesari S Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011, 4:233-242.
43. Ashwell JD, Vacchio MS, Galon J Do glucocorticoids participate in thymocyte development?. Immunol Today 2000, 21:644-646.
44. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 2000, 93:634-639.
45. Benedetti S, Pirola B, Poliani PL, et al. Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther 2003, 10:188-192.
46. Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999, 162:6473-6481.
47. Matasic R, Dietz AB, Vuk-Pavlovic S Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol 1999, 66:909-914.
48. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
49. Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010, 12:631-644.
50. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33:583-590.
51. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol 1994, 17:234-238.
52. Margolin K, ErnstoffMS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.